Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.6111 USD | -1.42% | -6.13% | +79.63% |
May. 09 | Monopar Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Apr. 16 | Monopar Therapeutics Files Provisional Patent for New MNPR-101 Construct | MT |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 10.82M |
---|---|---|---|---|---|
Net income 2024 * | -6M | Net income 2025 * | -9M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-1.67
x | P/E ratio 2025 * |
-1.94
x | Employees | 10 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 47.74% |
1 day | -1.42% | ||
1 week | -6.13% | ||
Current month | -7.42% | ||
1 month | -4.53% | ||
3 months | +7.21% | ||
6 months | +107.50% | ||
Current year | +79.63% |
Managers | Title | Age | Since |
---|---|---|---|
Founder | 40 | 14-11-30 | |
Kim Tsuchimoto
DFI | Director of Finance/CFO | 61 | 15-05-31 |
Laura Kelly
CTO | Chief Tech/Sci/R&D Officer | - | 21-02-17 |
Members of the board | Title | Age | Since |
---|---|---|---|
Michael Brown
BRD | Director/Board Member | 67 | 14-11-30 |
Arthur Klausner
BRD | Director/Board Member | 64 | 17-07-31 |
Kim Tsuchimoto
DFI | Director of Finance/CFO | 61 | 15-05-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-21 | 0.6111 | -1.42% | 38,257 |
24-05-20 | 0.6199 | +1.62% | 57,746 |
24-05-17 | 0.61 | -1.21% | 39,401 |
24-05-16 | 0.6175 | +3.24% | 34,442 |
24-05-15 | 0.5981 | -8.13% | 110,439 |
Delayed Quote Nasdaq, May 21, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+79.63% | 10.82M | |
+44.48% | 54.04B | |
+43.57% | 41.96B | |
-0.86% | 41.92B | |
-7.59% | 28.35B | |
+12.30% | 26.35B | |
-21.83% | 19B | |
+7.15% | 13B | |
+29.40% | 12.28B | |
+25.15% | 12.19B |
- Stock Market
- Equities
- MNPR Stock